All News
New ideas in gout management
d
EurekAlert!
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
Read Article
EULAR 2025 – Day 3 Report
Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
Read Article
#EULAR2025 Abstr#LB0007 Two’s Company, Three’s a Crowd! In 5 #SLE pts treated with CC312, a novel CD19/CD3/CD28 tri-specific ab in dose escalation showed rapid & B-cell depletion & all achieved SRI-4. No =>G2 CRS or ICANS. USP: off-the-shelf & overcome T-cell exhaustion @RheumNow https://t.co/6DZRj09JEQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Low disease activity more difficult to achieve in vulnerable populations.
All rheumatic diseases - #RA #PsA #AS
initiating DMARDs takes longer in these population
#EULAR2025 @RheumNow https://t.co/voIivshKRt
Bella Mehta bella_mehta ( View Tweet)
What do we know about disparities in #SLE
- worse in women
- worse in non white populations
- have lower quality of care in vulnerable populations
- have worse outcomes in vulnerable populations
#EULAR2025 @rheumnow
Diagnosis itself is difficult in communities with poor access https://t.co/pcUaJ0eK65
Bella Mehta bella_mehta ( View Tweet)
#Lupus is one of the biggest social discriminators
🔺️Higher prevalence in Women
🔺️Higher prevalence in Non-Whites
🔺️More catastrophic manifestations in low socioeconomic groups
Disaster Medicine Session
Social disparities and impact on outcomes
#EULAR2025
@RheumNow https://t.co/mewR9NzXHt
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Dual pandemic in Africa.
Increasing lifestyle diseases and obesity, along with infections and malnutrition.
These may be reflected in rheumatic diseases too (if they could be studied in detail)
#EULAR2025 @RheumNow https://t.co/6ulMRxX8az
Links:
Bella Mehta bella_mehta ( View Tweet)
Targets for OA pain pharmacotherapies
some by the wayside:
- NGF
- TrkA
but some very much in play and exciting:
- neurotrophin-3
- TRPV1
- Nav1.7, 1.8
Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo
David Liew drdavidliew ( View Tweet)
In the APEX Phase 3b RCT (N=1020), guselkumab (IL-23p19 inhibitor) significantly reduced radiographic progression (ΔvdH-S 0.55 & 0.54 vs 1.35 PBO; p≤0.002) and improved ACR20 (67–68% vs 47%) at W24 in biologic-naïve PsA. Safety consistent with prior data. Abstract LB0010 https://t.co/mFDsBsCg6m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used)
multiple aspects -
Individual, Providers and system level
Navigating health care systems
#EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe
Bella Mehta bella_mehta ( View Tweet)
RCT in axSpA (N=200): Digital therapeutic Axia added to stable treatment led to significant improvements in BASDAI (–1.66), BASFI (–1.12), ASQoL (–2.51), with ASAS20/40 responses of 51%/23% vs 9%/3% for usual care. Supports role of DTx in axSpA care. Abstract LB0002 @RheumNow https://t.co/oF6bjIwNIY
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
LEVI-04 (neutrophin-3 inhibitor presented as #ACR24 late-breaker in knee OA)
more good efficacy data, no rapidly progressive OA safety signal.
For us clinicians: impressive impact size, esp relative to alternatives.
Finally, something that works??
#EULAR2025 OP0374 @RheumNow https://t.co/iVdlwyaqrv
David Liew drdavidliew ( View Tweet)
It’s a hot topic at #EULAR2025, but the messages on AI in medicine from patient-professional discussions is clear:
- potential upside massive in many domains, but
- patients still want their clinicians by their side
#EULAR2025 meeting highlights @RheumNow https://t.co/4T6gE7TeQp
David Liew drdavidliew ( View Tweet)
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/S8iA0C4pwG
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
https://t.co/ycQT2dfVXe https://t.co/Qa58ofW411
Dr. John Cush RheumNow ( View Tweet)
Health Literacy Matters in Rheumatic Disease Care
Dr. Mrinalini Dey reports on abstract OP0026, "Health literacy associates with clinical, treatment and work status in people with inflammatory arthritis: Results from a national cohort", presented at EULAR 2025 in Barcelona, https://t.co/f45rxHBYnY
Dr. John Cush RheumNow ( View Tweet)
NMA of 14RCTs (>2500 pts) eval relative efficacy of bDMARDs and tsDMARDs in mostly biologic naïve nr-axSpA pts.
-All therapies studied significantly improved ASAS40 response rates compared to placebo.
-Certolizumab and Golimumab were the most effective therapies, followed by https://t.co/BJLRpEDYrv
Links:
Adela Castro AdelaCastro222 ( View Tweet)
👁️Uveitis in axSpA:
-Up to 40% can present before SpA dx
-NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis
-Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects.
#EULAR2025
@RheumNow https://t.co/mPuSMnD1Zs
Links:
Adela Castro AdelaCastro222 ( View Tweet)
In 30 axSpA pts (mean age 42 yrs, BASDAI 3.5, BASFI 2.8, BASMI 2.0, chest expansion 4.5 cm), an 8-wk individualized exercise (cardiorespiratory + trunk strength via cardiopulmonary exercise testing [CPET] & David Back Concept [DBC] devices) ↓ trunk strength deficit 14.1% & https://t.co/505cCEOzu1
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
